Cited by 234Bone Metabolism and DiseasesProstate Cancer Treatment and ResearchBone health and treatments

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Osteoprotegerin and RANK ligand expression in prostate cancer.

Brown, Julie M, Corey, Eva, Lee, Zandra D, True, Lawrence D, Yun, Theodore J, Tondravi, Mehrdad, Vessella, Robert L·2001·Urology

DOI 10.1016/s0090-4295(00)01122-5

Open this paper in CoChat — free account

Abstract

Objectives To investigate the expression of osteoprotegerin (OPG) and RANK ligand (RANKL) in human prostatic tissues. The factors regulating the increased turnover associated with prostate cancer (CaP) bone metastasis are unknown. OPG and RANKL are recently identified regulators of bone resorption and bone remodeling.Methods Tissues from 28 patients with CaP and from 4 normal organ donors were analyzed by reverse transcriptase-polymerase chain reaction and immunohistochemistry for the expression of OPG and RANKL.Results OPG and RANKL messages were detected in both normal and cancerous prostate samples. In the normal prostate, OPG protein was detected in luminal epithelial and stromal cells (5% to 65% and 15% to 70%, respectively) and RANKL immunoreactivity was observed in 15% to 50% of basal epithelial cells, 40% to 90% of luminal epithelial cells, and 70% to 100% of stromal cells. OPG was not detected in 8 of 10 primary CaP specimens; RANKL was heterogeneously expressed in 10 of 11 CaP specimens. The percentage of tumor cells expressing OPG and RANKL was significantly increased in all CaP bone metastases compared with nonosseous metastases or primary CaP.Conclusions CaP bone metastases were consistently immunoreactive for both OPG and RANKL compared with nonosseous metastases or primary CaP. The presence of these crucial bone resorption regulators in CaP bone metastases suggests a mechanism whereby CaP cells may modulate bone turnover and has profound implications for the establishment and development of CaP bone metastases in advanced disease.

Integrity signals

Registry

Crossref · 10.1016/s0090-4295(00)01122-5

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,224
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
RANK is essential for osteoclast and lymph node development.
Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S. D., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14363 · Cited by 1,183
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S.-I., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8697 · Cited by 775
Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95: 3597-602
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Cited by 650
Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells
Hofbauer, L. C., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., Riggs, B. L., & Khosla, S. (1999) · Bone · doi:10.1016/s8756-3282(99)00162-3 · Cited by 630
Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord
Honoré, P., Luger, N. M., Sabino, M. A. C., Schwei, M. J., Rogers, S. D., Mach, D. B., O'keefe, P. F., Ramnaraine, M. L. R., Clohisy, D. R., & Mantyh, P. W. (2000) · Nature Medicine · doi:10.1038/74999 · Cited by 497

Show all 18 references

Sorted by citations

Items 101–200 of 234

Bone markers in the management of patients with skeletal metastases
Demers, L. M. (2003) · Cancer · doi:10.1002/cncr.11127 · Cited by 35
Clinical usefulness of bone markers in prostate cancer with bone metastasis
Kamiya, N., Suzuki, H., Endo, T., Yano, M., Naoi, M., Nishimi, D., Kawamura, K., Imamoto, T., & Ichikawa, T. (2012) · International Journal of Urology · doi:10.1111/j.1442-2042.2012.03098.x · Cited by 34
Direct but not indirect co-culture with osteogenically differentiated human bone marrow stromal cells increases RANKL/OPG ratio in human breast cancer cells generating bone metastases
Arrigoni, C., Luca, P. D., Gilardi, M., Previdi, S., Broggini, M., & Moretti, M. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-238 · Cited by 34
The Bisphosphonate Olpadronate Inhibits Skeletal Prostate Cancer Progression in a Green Fluorescent Protein Nude Mouse Model
Yang, M., Burton, D. W., Geller, J., Hillegonds, D. J., Hastings, R. H., Deftos, L. J., & Hoffman, R. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2050 · Cited by 33
Cellular Plasticity in Prostate Cancer Bone Metastasis
Jadaan, D. Y., Jadaan, M. M., & McCabe, J. P. (2015) · Prostate Cancer · doi:10.1155/2015/651580 · Cited by 32
Receptor Activator of Nuclear Factor-κB Ligand (RANKL) Expression in Hepatocellular Carcinoma With Bone Metastasis
Sasaki, A., Ishikawa, K., Haraguchi, N., Inoue, H., Ishio, T., Shibata, K., Ohta, M., Kitano, S., & Mori, M. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9277-4 · Cited by 32
Sensitivity to Quorn mycoprotein ( Fusarium venenatum ) in a mould allergic patient: Table 1
Katona, S. J., & Kaminski, E. R. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.11.876-a · Cited by 34
Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications
Terpos, E., & Dimopoulos, M. A. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-0974-x · Cited by 31
Osteoprotegerin is expressed in colon carcinoma cells.
Pettersen, I., Bakkelund, W. H., Smedsrød, B. H., & Sveinbjørnsson, B. (2005) · PubMed · Cited by 31
Review: Castration-resistant prostate cancer: new science and therapeutic prospects
Joaquim Bellmunt, B., & Oh, W. K. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009359769 · Cited by 31
RANKL signaling in bone physiology and cancer
Dougall, W. C. (2007) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e3282f335be · Cited by 30
Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of parathyroid hormone-related protein and its parathyroid hormone 1 receptor, osteoprotegerin and receptor activator of nuclear factor-kB ligand
Pérez‐Martínez, F. C., Alonso, V., Sarasa-Corral, J. L., Nam-Cha, S.-H., Vela‐Navarrete, R., Manzarbeitia, F., Calahorra, F. J., & Esbrit, P. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.037853 · Cited by 30
The Osteoblastic and Osteoclastic Interactions in Spinal Metastases Secondary to Prostate Cancer
Dushyanthen, S., Cossigny, D. A. F., & Quan, G. M. Y. (2013) · Cancer Growth and Metastasis · doi:10.4137/cgm.s12769 · Cited by 31
Monitoring of skeletal progression of prostate cancer by GFP imaging, X‐ray, and serum OPG and PTHrP
Burton, D. W., Geller, J., Yang, M., Jiang, P. X., Barken, I., Hastings, R. H., Hoffman, R. M., & Deftos, L. J. (2004) · The Prostate · doi:10.1002/pros.20146 · Cited by 30
OPG, RANKL, and RANK in Cancer Metastasis: Expression and Regulation
Brown, J. M., Zhang, J., & Keller, E. T. (2004) · Cancer treatment and research · doi:10.1007/978-1-4419-9129-4_7 · Cited by 28
Self-citation
The PCa Tumor Microenvironment
Sottnik, J. L., Zhang, J., Macoska, J. A., & Keller, E. T. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0073-8 · Cited by 27
Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells?
Mori, K., Ando, K., Heymann, D., & Rédiní, F. (2009) · PubMed · doi:10.14670/hh-24.235 · Cited by 26
Receptor activator of nuclear factor-kappaB ligand (RANKL) as a novel prognostic marker in prostate carcinoma.
Pérez‐Martínez, F. C., Alonso, V., Sarasa, J. L., Manzarbeitia, F., Vela‐Navarrete, R., Calahorra, F. J., & Esbrit, P. (2008) · PubMed · doi:10.14670/hh-23.709 · Cited by 25
Targeting the receptor activator of nuclear factor‐κB (RANK) ligand in prostate cancer bone metastases
Fred Saad, C., Markus, R. A., & Goessl, C. D. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07364.x · Cited by 25
Bisphosphonate induces apoptosis and inhibits pro‐osteoclastic gene expression in prostate cancer cells
Asahi, H., Mizokami, A., Miwa, S., Keller, E. T., Koshida, K., & Namiki, M. (2006) · International Journal of Urology · doi:10.1111/j.1442-2042.2006.01360.x · Cited by 27
Change in Markers of Bone Metabolism with Chemotherapy for Advanced Prostate Cancer: Interleukin-6 Response Is a Potential Early Indicator of Response to Therapy
Ignatoski, K. M. W., Friedman, J. D., Escara-Wilke, J. F., Zhang, X., Daignault, S. D., Dunn, R. L., Smith, D. C., & Keller, E. T. (2008) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2008.0024 · Cited by 24
Osteoprotegerin secretion from prostate cancer is stimulated by cytokines, in vitro
Penno, H., Silfverswärd, C., Frost, A., Brändström, H., Nilsson, O., & Ljunggren, Ö. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00242-5 · Cited by 24
Targeting receptor activator of nuclear factor-kappa B as a new therapy for bone metastasis in non-small cell lung cancer
Peters, S., & Meylan, E. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835d720b · Cited by 23
Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand (RANKL) in the Serum of Healthy Adults
Jung, K., Lein, M., von Hößlin, K., Grosse, A., Roth, S., Possinger, K., & Lüftner, D. (2002) · The International Journal of Biological Markers · doi:10.1177/172460080201700306 · Cited by 23
Prostate Cancer Progression and Surrounding Microenvironment
Alberti, C. (2006) · The International Journal of Biological Markers · doi:10.1177/172460080602100204 · Cited by 23
Soluble ErbB3 Levels in Bone Marrow and Plasma of Men with Prostate Cancer
Lin, S.-H., Lee, Y., Choueiri, M., Wen, S., Mathew, P. F., Ye, X., Do, K.-A., Navone, N. M., Kim, J., Tu, S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0472 · Cited by 22
Distinct Osteomimetic Response of Androgen‐Dependent and Independent Human Prostate Cancer Cells to Mechanical Action of Fluid Flow: Prometastatic Implications
González, Á., de Durango, C. G., Alonso, V., Bravo, B., Gortázar, A. R., Wells, A. H., Forteza, J., & Vidal‐Vanaclocha, F. (2016) · The Prostate · doi:10.1002/pros.23270 · Cited by 22
Intra-tibial injection of human prostate cancer cell line CWR22 elicits osteoblastic response in immunodeficient rats.
Andersen, C., Bagi, C. M., & Adams, S. W. (2003) · PubMed · Cited by 21
Oral squamous cell carcinoma cells modulate osteoclast function by RANKL-dependent and -independent mechanisms
Tada, T., Shin, M., Fukushima, H., Okabe, K., Ozeki, S., Okamoto, M., & Jimi, E. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.09.015 · Cited by 21
Malignant B-Lymphoid Cells with Bone Lesions Express Receptor Activator of Nuclear Factor-κB Ligand and Vascular Endothelial Growth Factor to Enhance Osteoclastogenesis
Shibata, H., Abe, M., Hiura, K., Wilde, J., Moriyama, K., Sano, T., Kitazoe, K.-I., Hashimoto, T., Ozaki, S., Wakatsuki, S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0181 · Cited by 22
BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation
Pan, T., Lin, S.-C., Yu, K., Yu, G., Song, J. H., Lewis, V. O., Bird, J. E., Moon, B. S., Lin, P. P., Tannir, N. M., et al. (2017) · Neoplasia · doi:10.1016/j.neo.2017.11.002 · Cited by 20
RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease
Christoph, F., König, F., Lebentrau, S., Jandrig, B., Krause, H., Strenziok, R., & Schostak, M. (2017) · World Journal of Urology · doi:10.1007/s00345-017-2145-y · Cited by 20
Down-regulation of osteoprotegerin expression as a novel biomarker for colorectal carcinoma
Kim, H. S., Yoon, G., Do, S., Kim, S. J., & Kim, Y.-W. (2016) · Oncotarget · doi:10.18632/oncotarget.7885 · Cited by 20
Cancer of the prostate presenting with diffuse osteolytic metastatic bone lesions: a case report
Segamwenge, I. L., Mgori, N. K., AbdallahYussuf, S., Mukulu, C. N., Nakangombe, P., Ngalyuka, P. K., & Kidaaga, F. (2012) · Journal of Medical Case Reports · doi:10.1186/1752-1947-6-425 · Cited by 19
New trends in the treatment of bone metastasis
Keller, E. T., Dai, J., Escara-Wilke, J. F., Hall, C. L., Ignatoski, K. M. W., Taichman, R. S., & Keller, J. M. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21540 · Cited by 20
Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
Kraj, M. A., Owczarska, K., Sokołowska, U., Centkowski, P., Pogłód, R., & Kruk, B. (2005) · PubMed · Cited by 19
De novo steroidogenesis in tumor cells drives bone metastasis and osteoclastogenesis
Sandor, L. F., Huh, J. B., Benko, P., Hiraga, T., Póliska, S., Dobó‐Nagy, C., Simpson, J., Homer, N. Z. M., Mahata, B., & Győri, D. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113936 · Cited by 20
Sex-determining region Y (SRY) attributes to gender differences in RANKL expression and incidence of osteoporosis
Kodrič, K., Zupan, J., Kranjc, T., Komadina, R., Mlakar, V., Marc, J., & Lovšin, N. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0294-3 · Cited by 19
Molecular markers of tumor invasiveness in ameloblastoma: An update
Zhong, Y., Guo, W., Wang, L., & Chen, X. (2011) · Annals of Maxillofacial Surgery · doi:10.4103/2231-0746.92780 · Cited by 17
Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis
Kamiya, N., Suzuki, H., Endo, T., Takano, M., Yano, M., Naoi, M., Kawamura, K., Imamoto, T., Takanami, M., & Ichikawa, T. (2011) · International Journal of Clinical Oncology · doi:10.1007/s10147-011-0193-7 · Cited by 17
Rare presentation of intestinal amyloidosis with acute intestinal pseudo-obstruction and perforation
Ng, S., & Busmanis, I. A. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.11.876 · Cited by 17
The Role of Bone Microenvironment, Vitamin D and Calcium
Santini, D., Pantano, F., Vincenzi, B., Tonini, G., & Bertoldo, F. (2012) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-21892-7_2 · Cited by 15
Targeting regulatory T cells for improving cancer therapy: Challenges and prospects
Dwarakanath, B. S. R., Farooque, A., & Gupta, S. (2018) · Cancer Reports · doi:10.1002/cnr2.1105 · Cited by 15
Glucocorticoid Receptor Regulates TNFSF11 Transcription by Binding to Glucocorticoid Responsive Element in TNFSF11 Proximal Promoter Region
Lovšin, N., & Marc, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031054 · Cited by 16
RANK rs1805034 T>C Polymorphism Is Associated with Susceptibility of Esophageal Cancer in a Chinese Population
Yin, J., Wang, L., Tang, W., Wang, X., Lv, L., Shao, A., Shi, Y., Ding, G., Chen, S., & Gu, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101705 · Cited by 16
Osteolytic or mixed bone metastasis is not uncommon in patients with high-risk prostate cancer
Kurokawa, R., Kato, S., Koyama, H., Ishida, M., Kurokawa, M., Kuroda, R., Ushiku, T., Kume, H., & Abe, O. (2022) · European Journal of Radiology · doi:10.1016/j.ejrad.2022.110595 · Cited by 13
Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics
Chu, G. C., Chung, L. W. K., Gururajan, M., Hsieh, C., Josson, S., Nandana, S., Sung, S.-Y., Wang, R., Wu, B. J., & Zhau, H. E. (2018) · Asian journal of urology · doi:10.1016/j.ajur.2018.11.003 · Cited by 13
Bone metastases in prostate cancer: a targeted approach
Storey, J. A., & Torti, F. M. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32805e8787 · Cited by 13
Downregulation of osteoprotegerin expression in metastatic colorectal carcinoma predicts recurrent metastasis and poor prognosis
Moon, A., Do, S., Kim, H. S., & Kim, Y.-W. (2016) · Oncotarget · doi:10.18632/oncotarget.12686 · Cited by 12
Prostate Cancer
Nelson, W. G., Carter, H. B., DeWeese, T. L., Antonarakis, E. S., & Eisenberger, M. A. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00084-9 · Cited by 13
Proteome-wide analysis reveals potential therapeutic targets for Colorectal cancer: a two-sample mendelian randomization study
Cai, Y., Wu, Y., Liu, J., Pan, H., Deng, W., Sun, W., Xie, C., & Huang, X. (2023) · BMC Cancer · doi:10.1186/s12885-023-11669-6 · Cited by 12
Inhibitory effect of metformin on bone metastasis of cancer via OPG/RANKL/RANK system
Jian, W., Chen, T., Qin, S., Duan, Y., & Wang, G. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.08.032 · Cited by 12
Exosomal tumor necrosis factor‐α from hepatocellular cancer cells (Huh‐7) promote osteoclast differentiation
Li, C.-H., Palanisamy, K., Li, X., Yu, S., Wang, I., Li, C., & Sun, K. (2021) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30127 · Cited by 13
Molecular Diagnostics in Prostate Cancer
Hessels, D., Rittenhouse, H. G., & Schalken, J. A. (2005) · EAU Update Series · doi:10.1016/j.euus.2005.09.005 · Cited by 12
The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: Implications for association studies with human cancers
Waterman, E. A., Cross, N. A., Lippitt, J. M., Cross, S. S., Rehman, I., Holen, I., Hamdy, F. C., & Eaton, C. L. (2007) · International Journal of Cancer · doi:10.1002/ijc.22946 · Cited by 12
Inhibition of prostate cancer-meditated osteoblastic bone lesions by the low-calcemic analog 1α-hydroxymethyl-16-ene-26,27-bishomo-25-hydroxy vitamin D3
Peleg, S., Khan, F., Navone, N. M., CODY, D. D., Johnson, E. M., Pelt, C. S. V., & Posner, G. H. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2005.06.015 · Cited by 12
Loss of inhibition over master pathways of bone mass regulation results in osteosclerotic bone metastases in prostate cancer
Rentsch, C. A., Cecchini, M. G., & Thalmann, G. N. (2009) · Swiss Medical Weekly · doi:10.4414/smw.2009.12284 · Cited by 12
The many roles of RANKL-RANK signaling in bone, breast and cancer
Schramek, D., & Penninger, J. M. (2011) · IBMS BoneKEy · doi:10.1138/20110512 · Cited by 11
Phytoestrogen modulation of bone-related cytokines and its impact on cell viability in human prostate cancer cells
Alonso, V., Pérez‐Martínez, F. C., Calahorra, F. J., & Esbrit, P. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.07.005 · Cited by 11
Expression of RANK‐ligand in prostate cancer cell lines
Penno, H., Nilsson, O., Brändström, H., Winqvist, O., & Ljunggren, Ö. (2008) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510802460466 · Cited by 12
Hypercalcemia of Malignancy
Lamy, O., & Burckhardt, P. (2002) · American Journal of Cancer · doi:10.2165/00024669-200201040-00005 · Cited by 10
Pathophysiology and Pharmacological Targeting of Tumor-Induced Bone Disease: Current Status and Emerging Therapeutic Interventions
Labropoulou, V., Theocharis, A. D., Symeonidis, A. S., Skandalis, S. S., Karamanos, N. K., & Kalofonos, H. P. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795471275 · Cited by 10
Treatment of Metastatic Prostate Adenocarcinoma to the Calcaneus
Bibbo, C., Hatfield, P. S., & Albright, J. T. (2009) · The Journal of Foot & Ankle Surgery · doi:10.1053/j.jfas.2009.07.027 · Cited by 10
Upregulated osteoprotegerin expression promotes lung cancer cell invasion by increasing miR‑20a expression
Wan, K., Tu, Z., Liu, Z., Cai, Y., Chen, Y., & Ling, C. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10278 · Cited by 10
RANK Ligand: A Key Role in Cancer-Induced Bone Destruction?
Stenzl, A. (2009) · European Urology Supplements · doi:10.1016/j.eursup.2009.09.001 · Cited by 10
Are coroners’ necropsies necessary? A prospective study examining whether a “view and grant” system of death certification could be introduced into England and Wales
Leadbeatter, S., James, D., & Davison, A. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.11.878 · Cited by 10
Promoter Methylation Down-regulates Osteoprotegerin Expression in Ovarian Carcinoma
Kim, J., Kim, S. H., & Kim, H. S. (2019) · Anticancer Research · doi:10.21873/anticanres.13353 · Cited by 9
Treatment of Castration-Resistant Prostate Cancer
Antonarakis, E. S., Carducci, M. A., & Eisenberger, M. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00110-9 · Cited by 9
Role of denosumab in breast cancer
Bartsch, R., & Steger, G. G. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903146877 · Cited by 9
Expression of Osteoprotegrin Is Enhanced in Lung Cancer Tissues and Promotes Aggressive Cellular Traits in H3122 Lung Cancer Cells
Yu, Z., Sanders, A. J., Owen, S., Cheng, S., Yang, X., & Jiang, W. G. (2017) · Anticancer Research · doi:10.21873/anticanres.11820 · Cited by 7
Serum Osteoprotegerin and Sex Steroid Levels in Patients With Prostate Cancer
Varsavsky, M., Reyes‐García, R., Perez, M. D., Ramírez, A. R. G., Mijan, J. L., & Muñoz‐Torres, M. (2012) · Journal of Andrology · doi:10.2164/jandrol.111.014696 · Cited by 6
An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases
Maldonado-Gonzales, E., & Pietschmann, P. (2010) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-010-0812-3 · Cited by 6
Delineating role of NF‐κB and interacting cytokines during prostate cancer‐induced osteoclastogenesis
Jadli, M., Thakur, K., Aggarwal, N., Chhokar, A., Bibban, R., Singh, T., Bhat, A., & Bharti, A. C. (2020) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29856 · Cited by 7
Prostate Cancer
Nelson, W. G., Antonarakis, E. S., Carter, H. B., Marzo, A. M. D., & DeWeese, T. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00081-5 · Cited by 6
Physiopathologie et nouvelles stratégies thérapeutiques dans la prise en charge des métastases osseuses du cancer de la prostate
Lebrét, T., Méjean, A., & Houédé, N. (2011) · The French Journal of Urology · doi:10.1016/j.purol.2010.12.001 · Cited by 7
Bone Cancer Pain, Mechanism and Treatment
Sliepen, S. H. J. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.95910 · Cited by 5
Metastatic Bone Disease
Body, J. (2006) · Elsevier eBooks · doi:10.1016/b9-78-012088-5/62650-0492 · Cited by 5
Androgen receptor expression in ductal carcinoma in situ of the breast: relation to oestrogen and progesterone receptors
Kasami, M. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.11.879 · Cited by 5
Gene Therapy for Prostate Cancer Bone Metastasis
Hsieh, C., Kubo, H., & Chung, L. W. K. (2004) · Cancer treatment and research · doi:10.1007/978-1-4419-9129-4_11 · Cited by 5
Physiopathology of cancer metastases in bone and of the changes they induce in bone remodeling
BONUCCI, E. (2002) · RENDICONTI LINCEI · doi:10.1007/bf02904492 · Cited by 4
Breast Cancer: Rank Ligand Inhibition
Bartsch, R., Steger, G. G., Gnant, M., & Ziebermayr, R. (2010) · Breast Care · doi:10.1159/000321122 · Cited by 5
Remodelage osseux
Cohen-Solal, M. E., & de Vernejoul, M. C. (2003) · Therapies · doi:10.2515/therapie:2003063 · Cited by 4
Castration Resistant, Taxane Naïve Metastatic Prostate Cancer: Current Clinical Approaches and Future Directions
Gignac, G. A., Morris, M. J., & Hussain, M. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.04.033 · Cited by 4
Cell Biology of Prostate Cancer and Molecular Targets
Gleave, M. E., Cox, M., & Wang, Y. Z. (2010) · Springer eBooks · doi:10.1007/978-1-60327-829-4_1 · Cited by 3
Cytokines and Lymphomas
Georgakis, G. V., & Younes, A. (2005) · Springer eBooks · doi:10.1007/0-387-24361-5_4 · Cited by 3
Metástasis óseas: manejo multidisciplinario, conducta diagnóstica y terapéutica
Durand, J.-P., Karoubi, M., Anract, P., & Goldwasser, F. (2013) · EMC - Aparato Locomotor · doi:10.1016/s1286-935x(13)64172-6 · Cited by 3
Cancer in the Spine
Markman, M., McLain, R. F., Markman, M., Macklis, R. M., Lewandrowski, K., Bukowski, R. M., & Benzel, E. C. (2006) · Humana Press eBooks · doi:10.1007/978-1-59259-971-4 · Cited by 3
Contribution of osteoclasts to the bone–tumor niche
Edwards, J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-416721-6.00005-4 · Cited by 2
Mechanistic Role of RANKL in Cancer-induced Bone Diseases and Development of a Targeted Therapy to Inhibit this Pathway
Dougall, W. C. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374895-9.00032-3 · Cited by 2
Biology and Therapeutic Basis of Prostate Cancer Bone Metastasis
Keller, E. T. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-224-3_11 · Cited by 2
Androgen decreases osteoprotegerin expression in prostate cancer cells
Vandyke, K., Jackson, P., Rowe, A., Russell, P. J., & Blair, J. M. (2006) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500927 · Cited by 2
Métastases osseuses : prise en charge multidisciplinaire, approche diagnostique et thérapeutique
Durand, J.-P., Karoubi, M., Anract, P., & Goldwasser, F. (2012) · EMC - Appareil locomoteur · doi:10.1016/s0246-0521(12)55888-2 · Cited by 2
Transactivation of human osteoprotegerin promoter by GATA-3
Kao, S., & Stanković, K. M. (2015) · Scientific Reports · doi:10.1038/srep12479 · Cited by 2
Molecular cloning and functional characterization of the porcine extracellular domain of Receptor Activator of NF-κB Ligand (sRANKL)
Böcker, W., Radic, T., Schönitzer, V., Haasters, F., Mutschler, W., & Schieker, M. (2011) · Gene · doi:10.1016/j.gene.2011.08.008 · Cited by 2
Localized Osteolysis
Mundy, G. R., Edwards, C. M., Edwards, J., Lynch, C. C., Sterling, J. A. R., & Zhuang, J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00005-7 · Cited by 2
The role of serum osteoprotegerine in metastatic prostate cancer - a case control study.
Σιαμπανοπούλου, Μ., El, M., Moustakas, G. N., Haritanti, A., & Gotzamani‐Psarrakou, A. (2016) · Europe PMC (PubMed Central) · Cited by 2
Prostate Cancer Markers
Finlay, J. A., Mikolajczyk, S. D., Pribyl, T. M., Wallace, R. B., & Rittenhouse, H. G. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-791-8_7 · Cited by 2
RANK/RANKL Axis in Melanoma
Mori, K., Ando, K., Lézot, F., & Heym, D. (2011) · InTech eBooks · doi:10.5772/20518 · Cited by 1
Prolonged Antiresorptive Treatment of Lytic Prostate Cancer Xenografts in Mouse Bone Results in Tumor Necrosis
Blair, J., Modzelewski, J. R. K., Perryman, L., Russell, P. J., Seibel, M. J., & Dunstan, C. R. (2009) · doi:10.29685/jcm.200902.0003 · Cited by 1
Matrix Metalloproteinases as Key Regulators of Tumor–Bone Interaction
Lynch, C. C., & Matrisian, L. M. (2008) · Springer eBooks · doi:10.1007/978-0-387-69057-5_27 · Cited by 1

Authors: Brown, J. M., Corey, E., Lee, Z. D., True, L. D., Yun, T. J., Tondravi, M., & Vessella, R. L.
Affiliations: University of Washington (US)
American Red Cross (US)
Corresponding author: Brown, Julie M
ORCID: Brown, Julie M
Corey, Eva
True, Lawrence D
Yun, Theodore J
Venue: Urology
Publisher: Elsevier BV
Published: 2001-04
Volume: 57
Issue: 4
Pages: 611-616
ISSN: 0090-4295 (ISSN-L)
DOI: 10.1016/s0090-4295(00)01122-5
OpenAlex: W2114394594
Cited by: 234
References: 18
Citations by year: 2024: 1 · 2023: 5 · 2022: 1 · 2021: 7 · 2020: 5 · 2019: 2 · 2018: 3 · 2017: 6 · 2016: 6 · 2015: 6 · 2014: 5 · 2013: 9 · 2012: 14
FWCI: 5.82
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Urology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5p50dk047656-07)
National Institute of Diabetes and Digestive and Kidney Diseases (DK 47656-07)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords: osteoprotegerin, RANK ligand, prostate cancer, bone metastasis, bone resorption, bone remodeling, tumor stromal cells, luminal cells, bone turnover
MeSH terms: Aged, Aged, 80 and over, Base Sequence, Bone Neoplasms, Carrier Proteins, Glycoproteins, Humans, Immunohistochemistry, Lymphatic Metastasis, Male, Membrane Glycoproteins, Middle Aged, Prostate, Prostatic Neoplasms, RNA, Messenger, Cytokines, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Osteoprotegerin and RANK ligand expression in prostate cancer.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks